Copyright © 1999 by the BMJ Publishing Group Ltd.
Tackling antimicrobial resistance
Relevant BNF section: 5.1
Bacteria resistant to antibiotic therapy are becoming much more common and this has led to mounting concern in the UK and worldwide.1–4 Many pathogens are now 'multiresistant', that is, they are resistant to several classes of antimicrobial drug. Infection with such organisms may be particularly difficult to treat. In this article, we briefly discuss how resistance and multiresistance occur. We consider some of the important pathogens involved and the problems they pose in hospitals and the community. We discuss strategies for slowing the accumulation of antibiotic resistance and the implications for doctors treating patients with common infections.
This article has been cited by other articles:
![]() |
S. Denamur, F. Van Bambeke, M.-P. Mingeot-Leclercq, and P. M. Tulkens Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2236 - 2238. [Abstract] [Full Text] [PDF] |
||||
![]() |
Risks of extended-spectrum beta-lactamases DTB, March 1, 2008; 46(3): 21 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Clements, T. Stephenson, V. Gabriel, T. Harrison, M. Millar, A. Smyth, W. Tong, and C. J Linton Rationalised prescribing for community acquired pneumonia: a closed loop audit Arch. Dis. Child., October 1, 2000; 83(4): 320 - 324. [Abstract] [Full Text] [PDF] |
||||



